The list of symptoms that are now being seen to have links to COVID 19 infection are growing especially in the area of neurological and neuropsychiatric conditions. I think we are going to be seeing a large increase in people reporting these kinds of problems over the coming months and years and neurologists and mental health professionals are going to need all the tools they can muster to help their patients recover.
One very recently reported area of dysfunction is the brainstem which controls many basic life functions, include respiration, cardiovascular, gastrointestinal functions and neurological functions. We must be vigilant about making sure that the brain is protected against further injury from the COVID virus which can attack areas around the brain while not necessarily attacking the brain itself. Photobiomodulation is a way to treat the brain tissue that can provide protection against future injury while boosting the resources that are needed to help heal and improve overall brain functions.
Read the article here: https://pubmed.ncbi.nlm.nih.gov/33538586/
The point of the paper is to focus on the value of a particular RNA component that appears to regulate neuronal growth in the stem cell. The more mature cells in the brain, the better protection against degeneration was seen. Our research partners at Durham Univ. are keen to study the effects of photobiomodulation on Micro-RNA behavior and we are actively fund raising for to support these studies. Please consider helping us with this effort with a tax deductible donation to the QMF research fund.
The current efforts we've undertaken show that photobiomodulation has positive effects on mitochondria and other cellular components associated with neuronal health and resistance to damage. Our hope is that we can further clarify the specific mechanisms down to the most basic level in order to optimize the treatment models we can then develop for a wide range of neurodegenerative and neuropsychiatric conditions.
We can see this is an important aspect of how we may be able to intervene in the post-COVID long hauler syndromes that are emerging now, especially in neurology and psychiatry. It may be that targeted dosing of this treatment can bring about substantial improvement in patients now struggling just to survive the day.
I'm now at a new level in my efforts to influence public opinion regarding the use of noninvasive treatments for cognitive and behavioral symptoms associated with dementia. We've now had a report on a multi-site, randomized, placebo-controlled clinical trial conducted within the Dept. of Neurosurgery at Baylor Scott & White Medical Center which is affiliated with Texas A&M School of Medicine published in a peer-reviewed journal
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.